NASDAQ:IRTCIrhythm Technologies Stock Price, Forecast & News

Irhythm Technologies' stock was trading at $85.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IRTC shares have increased by 31.3% and is now trading at $112.29. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Irhythm Technologies.

Irhythm Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Irhythm Technologies.

Irhythm Technologies Inc (NASDAQ:IRTC) issued its earnings results on Thursday, May, 7th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.23. The business earned $63.50 million during the quarter, compared to analysts' expectations of $61.40 million. Irhythm Technologies had a negative return on equity of 49.99% and a negative net margin of 24.34%. Irhythm Technologies's revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.33) EPS. View Irhythm Technologies' earnings history.

8 brokerages have issued 1-year price targets for Irhythm Technologies' shares. Their forecasts range from $112.00 to $142.00. On average, they anticipate Irhythm Technologies' stock price to reach $130.67 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View analysts' price targets for Irhythm Technologies.

News headlines about IRTC stock have trended negative recently, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Irhythm Technologies earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Irhythm Technologies.

Some companies that are related to Irhythm Technologies include ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Novocure (NVCR), Tandem Diabetes Care (TNDM), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), NuVasive (NUVA), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP) and Inari Medical (NARI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Irhythm Technologies investors own include Alibaba Group (BABA), NVIDIA (NVDA), DexCom (DXCM), Paypal (PYPL), Teladoc Health (TDOC), Shopify (SHOP), Veeva Systems (VEEV), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and Paycom Software (PAYC).

(IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

Irhythm Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.04%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, Ralph Snyderman and Raymond W Scott. View institutional ownership trends for Irhythm Technologies.

IRTC stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Irhythm Technologies company stock in the last year include David A Vort, Kevin M King, Matthew C Garrett, Ralph Snyderman, and Raymond W Scott. View insider buying and selling activity for Irhythm Technologies.

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IRTC stock can currently be purchased for approximately $112.29.

Irhythm Technologies has a market capitalization of $3.04 billion and generates $214.55 million in revenue each year. The company earns $-54,570,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.

The official website for Irhythm Technologies is www.irhythmtech.com.

Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]